IL6 and myasthenia gravis: Monoclonal antibodies (mAbs) targeting IL6 or IL6 receptor has demonstrated clinical efficacy against many diseases, including preclinical models of MG, and a new anti-IL-6 receptor (Satralizumab) is currently undergoing a clinical trial for the treatment of MG.